Hemostasis Today

March, 2026
March 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Mohamed Sikkander Abdul Razak: Addressing Underdiagnosis of Bleeding Disorders in Women With Heavy Menstrual Bleeding
Mar 30, 2026, 14:21

Mohamed Sikkander Abdul Razak: Addressing Underdiagnosis of Bleeding Disorders in Women With Heavy Menstrual Bleeding

Mohamed Sikkander Abdul Razak, Professor at GKM College of Engineering Technology, shared Heghine Khachatryan’s post on LinkedIn:

1. Heavy menstrual bleeding (HMB) is described as:

The most common bleeding manifestation of underlying hemostatic defects, often underdiagnosed.

2. The mechanistic pathway explaining why bleeding occurs involves:

  • Endothelial integrity and angiogenesis: estrogen and progesterone cause a fragile endometrium with increased vascular density.
  • Primary hemostasis defect: von Willebrand factor (vWF) or platelet dysfunction – impaired adhesion and aggregation.
  • Secondary hemostasis impairment: reduced thrombin generation or fibrinolysis – unstable fibrin clot.
  • Clinical outcome: excessive and prolonged menstrual bleeding (HMB).

3. Most common causes of HMB are:

  • von Willebrand disease (vWD).
  • Platelet function disorders.
  • Mild factor deficiencies.

4. During pregnancy, hemostatic changes:

  • Mask bleeding disorders, but risks resurface as:
  • Increased miscarriage (early placental hemostasis failure).
  • Postpartum hemorrhage (rapid fibrinolysis plus uterine atony).
  • Maternal morbidity (unrecognized vWD or platelet defects).

5. Misdiagnosis of HMB can lead to:

  • Delayed diagnosis.
  • Severe anemia.
  • Obstetric and surgical complications.
  • Preventable morbidity.

6. HMB is often the:

First and only warning sign of a bleeding disorder.

7. Call to action for HMB management:

Hematologic evaluation is indicated in ALL women with HMB, especially:

  • Adolescents.
  • Those with iron deficiency or bleeding history.
  • Those planning pregnancy or surgery.

8. Key message about HMB:

It is not a ‘gynecologic’ issue; it is a hemostatic disorder until proven otherwise.”

Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared a post on LinkedIn:

“Heavy menstrual bleeding is not ‘normal’ — it is often missed pathology.

For too long, heavy menstrual bleeding (HMB) has been normalized, underestimated, and frequently misdiagnosed.

Behind what is often dismissed as a ‘gynecological issue’, there may be an underlying hemostatic disorder — including von Willebrand disease, platelet function defects, or other coagulation abnormalities.

The clinical reality is concerning:

Many women remain undiagnosed for years, presenting later with anemia, perioperative bleeding, or complications during pregnancy and childbirth.

Pregnancy introduces an additional layer of complexity.

Hemostasis is dynamically altered, and in women with unrecognized bleeding disorders, this may result in:

  • increased risk of miscarriage
  • postpartum hemorrhage
  • preventable maternal morbidity

Misdiagnosis is not benignit is systemic failure.

We must shift from symptom-based reassurance to structured hemostatic evaluation, especially in:

  • adolescents with HMB
  • women with iron deficiency
  • patients with bleeding history prior to surgical or reproductive interventions

This is not only a clinical issue — it is a matter of health equity, awareness, and diagnostic capacity.

The time has come to integrate hemostasis into routine women’s health assessment — not as an exception, but as a standard.”

Mohamed Sikkander Abdul Razak: Addressing Underdiagnosis of Bleeding Disorders in Women With Heavy Menstrual Bleeding

Other posts featuring Mohamed Sikkander Abdul Razak on Hemostasis Today.